Patents · 2022 · pending
Treatment of GPAM Related Diseases and Disorders
siRNA and antisense oligonucleotides targeting GPAM, for metabolic disorders including liver and cardiovascular conditions.
- Filings
- 2
- Status
- Pending
- First priority
- Jun 21, 2022